Destabilization of ERBB2 Transcripts by Targeting 3′ Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In addition to repressing ERBB2 promoter function, histone deacetylase (HDAC) inhibitors induce the accelerated decay of mature ERBB2 transcripts; the mechanism mediating this transcript destabilization is unknown but depends on the 3′ untranslated region (UTR) of ERBB2 mRNA. Using ERBB2-overexpressing human breast cancer cells (SKBR3), the mRNA stability factor HuR was shown to support ERBB2 transcript integrity, bind and endogenously associate with a conserved U-rich element within the ERBB2 transcript 3′ UTR, coimmunoprecipitate with RNA-associated HDAC activity, and colocalize with HDAC6. HDAC6 also coimmunoprecipitates with HuR in an RNA-dependent manner and within 6 hours of exposure to a pan-HDAC inhibitor dose, that does not significantly alter cytosolic HuR levels or HuR binding to ERBB2 mRNA. Cellular ERBB2 transcript levels decline while remaining physically associated with HDAC6. Knockdown of HDAC6 protein by small interfering RNA partially suppressed the ERBB2 transcript decay induced by either pan-HDAC or HDAC6-selective enzymatic inhibitors. Three novel hydroxamates, ST71, ST17, and ST80 were synthesized and shown to inhibit HDAC6 with 14-fold to 31-fold greater selectivity over their binding and inhibition of HDAC1. Unlike more potent pan-HDAC inhibitors, these HDAC6-selective inhibitors produced dose-dependent growth arrest of ERBB2-overexpressing breast cancer cells by accelerating the decay of mature ERBB2 mRNA without repressing ERBB2 promoter function. In sum, these findings point to the therapeutic potential of HuR and HDAC6-selective inhibitors, contrasting ERBB2 stability effects induced by HDAC6 enzymatic inhibition and HDAC6 protein knockdown, and show that ERBB2 transcript stability mechanisms include exploitable targets for the development of novel anticancer therapies. (Mol Cancer Res 2008;6(7):1250–8)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 3×
“previous studies have shown that HDAC6 is the primary source of most cytoplasmic HDAC enzymatic activities (10-13), Western analysis of HuR immunoprecipitates confirmed the”
BackgroundFischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754 · cited 1×
“The relative HDAC6-binding and -inhibitory specificity of the novel hydroxamates was tested using immunoprecipitated FLAG-tagged HDAC1 and HDAC6 subtypes (24, 25), and were scored as IC50 values calculated for each compound based on the inhibition of the enzymatic reactivity of a fluorescent small molecule substrate (…”
MethodSelf-citationMice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559 · cited 7×
“significantly more impaired by loss of HDAC6 catalytic function than by the total absence of HDAC6 protein (12).”
BackgroundInfluentialIdentification of a target RNA motif for RNA-binding protein HuR
de Silanes, I. L., Zhan, M., Lal, A., Yang, X., & Gorospe, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306453101 · Cited by 502 · cited 1×
“1A, embedded near the poly(A) tail of the ERBB2 3¶ UTR sequence is an evolutionarily conserved U-rich region (nucleotides 465-505) putatively capable of binding factors such as HuR or AUF1 that regulate mRNA stability (5, 6).”
BackgroundCabrero, J. R., Serrador, J. M., Barreiro, O., Mittelbrunn, M., Naranjo-Suárez, S., Martín-Cófreces, N., Vicente-Manzanares, M., Mazitschek, R., Bradner, J. E., Ávila, J., et al. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-01-0008 · Cited by 95 · cited 3×
“seem to be dependent on the noncatalytic BUZ (13, 14).”
Background
Cited by
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
“Furthermore, the pharmacologic inhibition of HDACs will almost certainly not be equivalent to genetic knockdown/ knockout (37), especially in terms of effects on multiprotein complex formation and function, and for less catalytically active HDACs such as those in class IIa.”
BackgroundHistone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Self-citationRecent advances in the discovery of potent and selective HDAC6 inhibitors
Wang, X.-X., Wan, R.-Z., & Liu, Z.-P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.040 · Cited by 152
Seo, J., Min, S. K., Park, H.-R., Kim, D. H., Kwon, M. J., Kim, L. S., & Ju, Y.-S. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.323 · Cited by 100
“[2] reported that high HDAC2 expression was significantly corre lated with overexpression of HER2, and in vitro studies have detected an association of HDAC6 and HER2 in oncogenic tu morigenesis [20].”
BackgroundStolfa, D. A., Marek, M., Lancelot, J., Hauser, A.-T., Walter, A., Leproult, E., Melesina, J., Rumpf, T., Wurtz, J.-M., Cavarelli, J., et al. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.03.007 · Cited by 75
“As analogues of SAHA, we used a newly synthesized carboxylic acid derivative (SAHA-COOH), the HDAC6-selective inhibitor ST80 [19], crebinostat [20] and hexanoylhydroxamate (HHA) that does not have an aromatic capping group.”
MethodSelf-citation
Metadata
- Authors
- Scott, G. K., Marx, C., Berger, C. E., Saunders, L. R., Verdin, E., Schäfer, S., Jung, M., & Benz, C. C.
- Venue
- Molecular Cancer Research
- Published
- 2008-07-01
- Volume
- 6
- Issue
- 7
- Pages
- 1250-1258
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2165459745
- Cited by
- 58
- References
- 5
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Destabilization of ERBB2 Transcripts by Targeting 3′ Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-07-2110
- The paper
- Scott, G. K., Marx, C., Berger, C. E., Saunders, L. R., Verdin, E., Schäfer, S., Jung, M., & Benz, C. C. (2008). Destabilization of ERBB2 Transcripts by Targeting 3′ Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-07-2110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.